The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1366
In Brief: An Aromatase Inhibitor Is Reported to Prevent Postmenopausal Breast Cancer
Download PDF:   US English
 Select a term to see related articles  Aromasin   Aromatase inhibitors   Breast Cancer   Exemestane 

A randomized, placebo-controlled, double-blind trial of exemestane (Aromasin, and others) in postmenopausal women considered at increased risk for breast cancer found that the aromatase inhibitor, over a median follow-up of 35 months, significantly decreased the annual incidence of invasive breast cancer from 0.55% to 0.19% (PE Goss et al. N Engl J Med, epub June 4, 2011).

© The Medical Letter, Inc. All Rights Reserved.
This article has been freely provided.